Literature DB >> 15550451

Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.

Jorge Manzanares1, Sergio Ortiz, José M Oliva, Sandra Pérez-Rial, Tomás Palomo.   

Abstract

Over the past few years, advances in the investigation of the neurochemical circuits involved in the development and treatment of alcohol dependence have identified peptides and receptors as potential key targets in the treatment of problems related to alcohol consumption. The endogenous opioid system is modified by alcohol intake in areas of the brain related to reward systems, and differential basal levels of opioid gene expression are found in rodents with a high preference for ethanol. This suggests a greater vulnerability to alcohol consumption in relation to differences in genetic background. Further evidence of the involvement of opioid peptides in alcohol dependence is the ability of the opioid antagonist naltrexone to reduce alcohol intake in animal models of dependence and in alcohol-dependent patients. Abundant evidence indicates that the activation of cannabinoid receptors stimulates the release of opioid peptides, therefore the cannabinoid receptor antagonists may presumably alter opioid peptide release, thus facilitating the reduction of ethanol consumption. However, little is known about the effects of ethanol on the endogenous cannabinoid system, the vulnerability of cannabinoid receptors to alcohol intake or their neurochemical implications in reducing consumption of alcohol. In this paper, we review the role of opioid and cannabinoid receptor systems, their vulnerability to alcohol intake and the development of dependence, and the targeting of these systems in the treatment of alcoholism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550451     DOI: 10.1093/alcalc/agh112

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  8 in total

1.  Voluntary alcohol drinking enhances proopiomelanocortin gene expression in nucleus accumbens shell and hypothalamus of Sardinian alcohol-preferring rats.

Authors:  Yan Zhou; Giancarlo Colombo; Keiichi Niikura; Mauro A M Carai; Teresa Femenía; Maria S García-Gutiérrez; Jorge Manzanares; Ann Ho; Gian Luigi Gessa; Mary Jeanne Kreek
Journal:  Alcohol Clin Exp Res       Date:  2012-06-22       Impact factor: 3.455

Review 2.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 4.  How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.

Authors:  Peter Clapp; Sanjiv V Bhave; Paula L Hoffman
Journal:  Alcohol Res Health       Date:  2008

Review 5.  Ethanol drinking in rodents: is free-choice drinking related to the reinforcing effects of ethanol?

Authors:  Alexis S Green; Nicholas J Grahame
Journal:  Alcohol       Date:  2008-02       Impact factor: 2.405

Review 6.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

7.  Interactions between ethanol and the endocannabinoid system at GABAergic synapses on basolateral amygdala principal neurons.

Authors:  Giuseppe Talani; David M Lovinger
Journal:  Alcohol       Date:  2015-10-27       Impact factor: 2.405

8.  Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.

Authors:  Adriano Mollica; Sveva Pelliccia; Valeria Famiglini; Azzurra Stefanucci; Giorgia Macedonio; Annalisa Chiavaroli; Giustino Orlando; Luigi Brunetti; Claudio Ferrante; Stefano Pieretti; Ettore Novellino; Sandor Benyhe; Ferenc Zador; Anna Erdei; Edina Szucs; Reza Samavati; Szalbolch Dvrorasko; Csaba Tomboly; Rino Ragno; Alexandros Patsilinakos; Romano Silvestri
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.